FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3132956138> ?p ?o ?g. }

• W3132956138 endingPage "02" @default.
• W3132956138 startingPage "PS9" @default.
• W3132956138 abstract "Abstract Background: The FDA approved neratinib (N), an irreversible pan-HER tyrosine kinase inhibitor, in combination with capecitabine (C) for patients with HER2+ advanced or metastatic breast cancer who have received ≥2 prior HER2-directed regimens in the metastatic setting based on the NALA clinical study, where N+C significantly improved PFS vs. lapatinib (L)+C. Characterizing HRQoL associated with this regimen can help inform treatment decision-making for these patients. The objective of this analysis was to characterize HRQoL among patients with HER2+ metastatic breast cancer from the NALA clinical study. Methods: NALA was a multinational, randomized, open-label, phase III clinical study of N+C vs. L+C in patients with HER2+ metastatic breast cancer and ≥2 prior HER2-directed regimens. From May 2013 to July 2017, patients were randomized 1:1 to N (240 mg qd) + C (750 mg/m2 bid 14d/21d) with loperamide prophylaxis during the first cycle, or to L (1250 mg qd) + C (1000 mg/m2 bid 14d/21d). HRQoL, a prespecified secondary endpoint of the NALA study, was measured using the EORTC QLQ-C30 and the breast cancer-specific QLQ-BR23 at baseline and every 6 weeks (±3 days) until the end of treatment (data collection through treatment cycle 19, 12.5 months). The QLQ-C30 summary and global health status scores range from 0 (worst) to 100 (best) and the systemic therapy side-effects scores range from 0 (best) to 100 (worst). Patients were included in the analysis for a particular scale if they had a baseline assessment and at least 1 follow-up assessment. For these analyses, a change of ≥10 points was considered to be clinically meaningful. Descriptive statistics summarized observed scores and changes from baseline, Kaplan-Meier and log-rank tests were used for time-to-deterioration (TTD) of ≥10 points and mixed models estimated the change over time for 7 prespecified scales: QLQ-C30 summary score, global health status, physical functioning, fatigue, constipation and diarrhea, and the EORTC QLQ-BR23 systemic therapy side effects subscale. No adjustments for multiplicity were performed. Results: 621 patients from 28 countries were randomized (307 N+C; 314 L+C). The mean completion rate of the QLQ-C30 over the course of the study was 91% for both treatment arms. Discontinuation due to any treatment-emergent adverse event (TEAE) was lower in the N+C vs. L+C arm (14% vs. 18%). At baseline, the mean (SD) QLQ-C30 summary scores were 79.8 (14.1) for N+C and 79.9 (15.7) for L+C. After 19 treatment cycles, the mean (SD) QLQ-C30 summary scores were similar to baseline scores: 81.8 (16.7) for N+C and 81.3 (15.3) for L+C. There were no differences in TTD of ≥10 points for the QLQ-C30 summary score between treatment arms; the HR for N+C vs. L+C was 0.94 (95% CI 0.63-1.40). All prespecified HRQoL subscales had similar statistically non-significant results for TTD with the exception of diarrhea (HR=1.71; 95% CI 1.32-2.23). The mixed models analyzing change in HRQoL from baseline did not demonstrate persistent declines nor meaningful differences between the treatment arms. Conclusion: In these results from the NALA study, among patients with HER2+ metastatic breast cancer, at study end and throughout most of the study, there were no differences observed between the two treatment arms in HRQoL scores. HRQoL was sustained over the study period despite the early transient presence of diarrhea in some patients. Discontinuation due to any TEAE was lower in the N+C vs. the L+C arm. These results may help guide healthcare providers, patients and carers in selection of optimal treatment for HER2+ metastatic breast cancer. Citation Format: Beverly Moy, Mafalda Oliveira, Cristina Saura, William Gradishar, Sung-Bae Kim, Adam Brufsky, Sara Hurvitz, Larisa Ryvo, Daniele Fagnani, Nancy Chan, Sujith R Kalmadi, Paula Silverman, Suzette Delaloge, Richard Bryce, Kiana Keyvanjah, Judith Bebchuk, Bo Zhang, Nina Oestreicher, Ron Bose. Neratinib + capecitabine sustains health-related quality of life (HRQoL) while improving progression-free survival (PFS) in patients with HER2+ metastatic breast cancer and ≥2 prior HER2-directed regimens [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS9-02." @default.
• W3132956138 created "2021-03-01" @default.
• W3132956138 creator A5001373717 @default.
• W3132956138 creator A5002647602 @default.
• W3132956138 creator A5011877804 @default.
• W3132956138 creator A5012218557 @default.
• W3132956138 creator A5017550097 @default.
• W3132956138 creator A5019978374 @default.
• W3132956138 creator A5026459010 @default.
• W3132956138 creator A5044108002 @default.
• W3132956138 creator A5047440506 @default.
• W3132956138 creator A5053983312 @default.
• W3132956138 creator A5067312354 @default.
• W3132956138 creator A5067980470 @default.
• W3132956138 creator A5068059897 @default.
• W3132956138 creator A5073619855 @default.
• W3132956138 creator A5081735541 @default.
• W3132956138 creator A5082195410 @default.
• W3132956138 creator A5083142899 @default.
• W3132956138 creator A5085136554 @default.
• W3132956138 creator A5085464902 @default.
• W3132956138 date "2021-02-15" @default.
• W3132956138 modified "2023-09-27" @default.
• W3132956138 title "Abstract PS9-02: Neratinib + capecitabine sustains health-related quality of life (HRQoL) while improving progression-free survival (PFS) in patients with HER2+ metastatic breast cancer and ≥2 prior HER2-directed regimens" @default.
• W3132956138 doi "https://doi.org/10.1158/1538-7445.sabcs20-ps9-02" @default.
• W3132956138 hasPublicationYear "2021" @default.
• W3132956138 type Work @default.
• W3132956138 sameAs 3132956138 @default.
• W3132956138 citedByCount "1" @default.
• W3132956138 countsByYear W31329561382021 @default.
• W3132956138 crossrefType "journal-article" @default.
• W3132956138 hasAuthorship W3132956138A5001373717 @default.
• W3132956138 hasAuthorship W3132956138A5002647602 @default.
• W3132956138 hasAuthorship W3132956138A5011877804 @default.
• W3132956138 hasAuthorship W3132956138A5012218557 @default.
• W3132956138 hasAuthorship W3132956138A5017550097 @default.
• W3132956138 hasAuthorship W3132956138A5019978374 @default.
• W3132956138 hasAuthorship W3132956138A5026459010 @default.
• W3132956138 hasAuthorship W3132956138A5044108002 @default.
• W3132956138 hasAuthorship W3132956138A5047440506 @default.
• W3132956138 hasAuthorship W3132956138A5053983312 @default.
• W3132956138 hasAuthorship W3132956138A5067312354 @default.
• W3132956138 hasAuthorship W3132956138A5067980470 @default.
• W3132956138 hasAuthorship W3132956138A5068059897 @default.
• W3132956138 hasAuthorship W3132956138A5073619855 @default.
• W3132956138 hasAuthorship W3132956138A5081735541 @default.
• W3132956138 hasAuthorship W3132956138A5082195410 @default.
• W3132956138 hasAuthorship W3132956138A5083142899 @default.
• W3132956138 hasAuthorship W3132956138A5085136554 @default.
• W3132956138 hasAuthorship W3132956138A5085464902 @default.
• W3132956138 hasConcept C121608353 @default.
• W3132956138 hasConcept C126322002 @default.
• W3132956138 hasConcept C143998085 @default.
• W3132956138 hasConcept C159110408 @default.
• W3132956138 hasConcept C197934379 @default.
• W3132956138 hasConcept C203092338 @default.
• W3132956138 hasConcept C2775930923 @default.
• W3132956138 hasConcept C2776694085 @default.
• W3132956138 hasConcept C2777329042 @default.
• W3132956138 hasConcept C2777909004 @default.
• W3132956138 hasConcept C2778375690 @default.
• W3132956138 hasConcept C2779413316 @default.
• W3132956138 hasConcept C2779786085 @default.
• W3132956138 hasConcept C2779951463 @default.
• W3132956138 hasConcept C2780739268 @default.
• W3132956138 hasConcept C2781413609 @default.
• W3132956138 hasConcept C526805850 @default.
• W3132956138 hasConcept C530470458 @default.
• W3132956138 hasConcept C535046627 @default.
• W3132956138 hasConcept C71924100 @default.
• W3132956138 hasConceptScore W3132956138C121608353 @default.
• W3132956138 hasConceptScore W3132956138C126322002 @default.
• W3132956138 hasConceptScore W3132956138C143998085 @default.
• W3132956138 hasConceptScore W3132956138C159110408 @default.
• W3132956138 hasConceptScore W3132956138C197934379 @default.
• W3132956138 hasConceptScore W3132956138C203092338 @default.
• W3132956138 hasConceptScore W3132956138C2775930923 @default.
• W3132956138 hasConceptScore W3132956138C2776694085 @default.
• W3132956138 hasConceptScore W3132956138C2777329042 @default.
• W3132956138 hasConceptScore W3132956138C2777909004 @default.
• W3132956138 hasConceptScore W3132956138C2778375690 @default.
• W3132956138 hasConceptScore W3132956138C2779413316 @default.
• W3132956138 hasConceptScore W3132956138C2779786085 @default.
• W3132956138 hasConceptScore W3132956138C2779951463 @default.
• W3132956138 hasConceptScore W3132956138C2780739268 @default.
• W3132956138 hasConceptScore W3132956138C2781413609 @default.
• W3132956138 hasConceptScore W3132956138C526805850 @default.
• W3132956138 hasConceptScore W3132956138C530470458 @default.
• W3132956138 hasConceptScore W3132956138C535046627 @default.
• W3132956138 hasConceptScore W3132956138C71924100 @default.
• W3132956138 hasIssue "4_Supplement" @default.
• W3132956138 hasLocation W31329561381 @default.
• W3132956138 hasOpenAccess W3132956138 @default.
• W3132956138 hasPrimaryLocation W31329561381 @default.
• W3132956138 hasRelatedWork W2129060478 @default.
• W3132956138 hasRelatedWork W2944015322 @default.
• W3132956138 hasRelatedWork W2944505249 @default.
• W3132956138 hasRelatedWork W3005901901 @default.

• next